
What is claimed is:

1. A method of treating breast cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I),



(I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein:

each R^1 and each R^2 is independently selected from the group consisting of halo, OR_5, $N(R_5)(R_6)$, NO_2, CN, $SO_2(R_5)$, C_1-C_6 alkyl and C_3-C_6 cycloalkyl;

R_3 and R_4 are either both hydrogen or, taken together with the carbon to which they are attached, form a carbonyl;

each R_5 and each R_6 is independently selected from the group consisting of hydrogen, C_1-C_6 alkyl and C_3-C_6 cycloalkyl;

m is 0, 1, 2, 3, 4, or 5; and

n is 0, 1, 2, 3, or 4,

wherein the therapeutically effective amount of the compound of Formula (I) is about 10 mg to about 1000 mg.

2. The method of claim 1, wherein the breast cancer is ER+, HER2-.

3. The method of claim 1 or 2, wherein the breast cancer is metastatic or locally advanced.

4. The method of any one of claims 1-3, wherein R^1 and R^2 are each independently selected from the group consisting of halo and OR_5.

5. The method of any one of claims 1-4, wherein R_3 and R_4 are both hydrogen.


6. The method of any one of claims 1-4, wherein R_3 and R_4, taken together with the carbon to which they are attached, form a carbonyl.

7. The method of any one of claims 1-3, 5, or 6, wherein m and n are each 0.


8. The method of any one of claims 1-6, wherein m and n are each 1.

9. The method of any one of claims 1-3, 5, or 6, wherein one of m and n is 0 and the other is 1.


10. The method of any one of claims 1-3, wherein the compound of Formula (I) is:





(I-a);





(I-b);


(I-c);



(I-d);


(I-e);



(I-f);



(I-g);




(I-h); or



(I-i);

or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug of any of the foregoing.

11. The method of any one of claims 1-3, wherein the compound of Formula (I) is a compound of Formula (I-c):



12. The method of any one of claims 1-11, wherein the compound of Formula (I) is administered orally to the subject.

13. The method of any one of claims 1-12, wherein the therapeutically effective amount of the compound of Formula (I) is administered to the subject once a day, twice a day, three times a day, or four times a day.

14. The method of any one of claims 1-13, wherein the therapeutically effective amount of the compound of Formula (I) is administered to the subject once a day.

15. The method of claims 1-12, wherein the therapeutically effective amount of the compound of Formula (I) is administered to the subject all at once or is administered in two, three, or four portions.

16. The method of any one of claims 1-15, wherein the therapeutically effective amount of the compound of Formula (I) is about 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg.

17. The method of any one of claims 1-15, wherein the therapeutically effective amount of the compound of Formula (I) is about 20 mg to about 750 mg.

18. The method of any one of claims 1-15, wherein the therapeutically effective amount of the compound of Formula (I) is about 30 mg to about 500 mg.

19. The method of any one of claims 1-15, wherein the therapeutically effective amount of the compound of Formula (I) is about 30 mg to about 120 mg.

20. The method of any one of claims 1-19, wherein the therapeutically effective amount of the compound of Formula (I) results in a mean day 15 AUC_{TAU} of greater than about 3,500 ng*hr/mL, greater than about 3,600 ng*hr/mL, greater than about 3,700 ng*hr/mL, greater than about 3,800 ng*hr/mL, greater than about 3,900 ng*hr/mL, greater than about 4,000 ng*hr/mL, greater than

about 4,100 ng*hr/mL, greater than about 4,200 ng*hr/mL, greater than about 4,300 ng*hr/mL, greater than about 4,400 ng*hr/mL, greater than about 4,500 ng*hr/mL, greater than about 4,600 ng*hr/mL, greater than about 4,700 ng*hr/mL, greater than about 4,800 ng*hr/mL, greater than about 4,900 ng*hr/mL, or greater than about 5,000 ng*hr/mL.

21. The method of any one of claims 1-19, wherein the therapeutically effective amount of the compound of Formula (I) results in a mean day 15 AUC_{TAU} of greater than about 4,000 ng*hr/mL and less than about 4,500 ng*hr/mL.

22. The method of any one of claims 1-21, wherein the therapeutically effective amount of the compound of Formula (I) results in a mean day 15 C_{max} of greater than about 200 ng/mL, greater than about 205 ng/mL, greater than about 210 ng/mL, greater than about 215 ng/mL, greater than about 220 ng/mL, greater than about 225 ng/mL, greater than about 230 ng/mL, greater than about 235 ng/mL, greater than about 240 ng/mL, greater than about 245 ng/mL, or greater than about 250 ng/mL.

23. The method of any one of claims 1-21, wherein the therapeutically effective amount of the compound of Formula (I) results in a mean day 15 C_{max} of greater than about 215 ng/mL and less than about 235 ng/mL.

24. The method of any one of claims 1-23, wherein the compound of Formula (I) is formulated as a tablet.

25. The method of claim 24, wherein the tablet comprises a compound of Formula (I) and, optionally, one or more of the following: emulsifier; surfactant; binder; disintegrant; glidant; and lubricant.

26. The method of claim 25, wherein the emulsifier is hypromellose.

27. The method of claim 25, wherein the surfactant is vitamin E polyethylene glycol succinate.

28. The method of claim 25, wherein the binder is microcrystalline cellulose or lactose monohydrate.

29. The method of claim 25, wherein the disintegrant is croscarmellose sodium.

30. The method of claim 25, wherein the glidant is silicon dioxide.

31. The method of claim 25, wherein the lubricant is sodium stearyl fumarate.

32. The method of any one of claims 1-31, further comprising the administration of a therapeutically effective amount of a CDK4/6 inhibitor to the subject in need thereof.

33. The method of claim 32, wherein the CDK4/6 inhibitor is SHR6390, trilaciclib, lerociclib, AT7519M, dinaciclib, ribociclib, abemaciclib, or palbociclib.

34. The method of claim 32, wherein the CDK4/6 inhibitor is palbociclib.

35. The method of claim 34, wherein the therapeutically effective amount of palbociclib is administered to the subject once a day.

36. The method of claims 34 or 35, wherein the therapeutically effective amount of palbociclib is 60 mg, 75 mg, 100 mg, or 125 mg.

37. The method of any one of claims 33-36, wherein the palbociclib is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days off treatment, wherein the cycle of treatment with palbociclib followed by off treatment is repeated one, two, three, four, five, or more times.


38. The method of any one of claims 1-37, wherein the compound of Formula (I) is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days off


treatment, wherein the cycle of treatment with the compound of Formula (I) followed by off treatment is repeated one, two, three, four, five, or more times.


39. The method of any one of claims 1-38, wherein the subject is in a fed state.


40. The method of any one of claims 1-38, wherein the subject is in a fasted state.

41. A method of treating metastatic breast cancer in a subject in need thereof, comprising once a day, oral administration of a therapeutically effective amount of the compound of Formula (I), wherein the compound of Formula (I) is:



(I-a);


(I-b);



(I-c);




(I-d);




(I-e);




(I-f);




(I-g);


(I-h); or


(I-i);

or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug of any of the foregoing.

42. The method of claim 41, wherein the compound of Formula (I) is a compound of Formula (I-c):



43. The method of claim 41 or 42, wherein the therapeutically effective amount of the compound of Formula (I) is administered to the subject all at once or is administered in two, three, or four portions.

44. The method of any one of claims 41-43, wherein the therapeutically effective amount of the compound of Formula (I) is about 30 mg to about 1000 mg.

45. The method of any one of claims 41-44, wherein the compound of Formula (I) is formulated as a tablet.

46. The method of any one of claims 41-45, further comprising the administration of a therapeutically effective amount of a CDK4/6 inhibitor to the subject in need thereof.

47. The method of claim 46, wherein the CDK4/6 inhibitor is SHR6390, trilaciclib, lerociclib, AT7519M, dinaciclib, ribociclib, abemaciclib, or palbociclib.

48. The method of claim 46, wherein the CDK4/6 inhibitor is palbociclib.

49. The method of claim 48, wherein the therapeutically effective amount of palbociclib is administered to the subject once a day.

50. The method of claims 48 or 49, wherein the therapeutically effective amount of palbociclib is 60 mg, 75 mg, 100 mg, or 125 mg.

51. The method of any one of claims 48-50, wherein the palbociclib is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days off treatment, wherein the cycle of treatment with palbociclib followed by off treatment is repeated one, two, three, four, five, or more times.

52. The method of any one of claims 41-51, wherein the compound of Formula (I) is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days off treatment, wherein the cycle of treatment with the compound of Formula (I) followed by off treatment is repeated one, two, three, four, five, or more times.

53. The method of any one of claims 41-52, wherein the subject is in a fed state.


54. The method of any one of claims 41-52, wherein the subject is in a fasted state.

55. The method of any one of claims 46-54, wherein the administration of the CDK4/6 inhibitor occurs before the administration of the compound of Formula (I).

56. The method of claim 55, wherein the administration of the CDK4/6 inhibitor occurs at least 30 minutes before the administration of the compound of Formula (I).


57. The method of any one of claims 46-54, wherein the administration of the CDK4/6 inhibitor occurs after the administration of the compound of Formula (I).

58. The method of claim 57, wherein the administration of the CDK4/6 inhibitor occurs at least 30 minutes after the administration of the compound of Formula (I).

59. A method of treating metastatic breast cancer in a subject in need thereof, comprising:
(i) once a day, oral administration of a therapeutically effective amount of a compound of Formula (I-c), , or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, and
(ii) once a day, oral administration of palbociclib.

60. A method of treating metastatic breast cancer in a subject in need thereof, comprising:

(i) once a day, oral administration of a therapeutically effective amount of a compound of



Formula (I-c), , and

(ii) once a day, oral administration of palbociclib.

61. The method of claim 59 or claim 60, wherein the therapeutically effective amount of the compound of Formula (I-c) is about 30 mg to about 1000 mg.

62. The method of any one of claims 59-61, wherein the therapeutically effective amount of palbociclib is 60 mg, 75 mg, 100 mg, or 125 mg.

63. The method of any one of claims 59-62, wherein the palbociclib is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days off treatment, wherein the cycle of treatment with palbociclib followed by off treatment is repeated one, two, three, four, five, or more times.

64. The method of any one of claims 59-62, wherein the compound of Formula (I-c) is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days off treatment, wherein the cycle of treatment with the compound of Formula (I-c) followed by off treatment is repeated one, two, three, four, five, or more times.

65. The method of any one of claims 59-64, wherein the subject is in a fed state.

66. The method of any one of claims 59-64, wherein the subject is in a fasted state.


67. The method of any one of claims 59-66, wherein the administration of palbociclib occurs before the administration of the compound of Formula (I-c).

68. The method of claim 67, wherein the administration of palbociclib occurs at least 30 minutes before the administration of the compound of Formula (I-c).

69. The method of any one of claims 59-66, wherein the administration of palbociclib occurs after the administration of the compound of Formula (I-c).

70. The method of claim 69, wherein the administration of palbociclib occurs at least 30 minutes after the administration of the compound of Formula (I-c).


71. A method for selective estrogen receptor degradation in a patient comprising:

(i) once a day, oral administration of a therapeutically effective amount of a compound of Formula (I-c), , or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, and

(ii) once a day, oral administration of palbociclib.

72. A method for inhibiting a cyclin-dependent kinase in a subject in need thereof comprising:

(i) once a day, oral administration of a therapeutically effective amount of a compound of




Formula (I-c), , or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, and

(ii) once a day, oral administration of palbociclib.

73. A kit comprising:

(i) a compound of Formula (I-c),




,

(ii) palbociclib, and

(iii) instructions for use.


74. A liquid composition comprising a surfactant, a solvent, and a compound of Formula (I-c):



75. The liquid composition of claim 74, wherein the surfactant is Tween 80.

76. The liquid composition of claim 74 or 75, wherein the solvent is PEG-400.

77. A method of making a liquid composition comprising a surfactant, a solvent, and a compound of Formula (I-c):



comprising the step of adding the solvent to a pre-aliquoted volume of the surfactant.

78. The method of claim 77, wherein the surfactant is Tween 80.

79. The method of claim 77 or 78, wherein the solvent is PEG-400.